Karim Estephan

Karim Estephan

Auto-generated profile, based on publicly available information

Karim Estephan

Department of Neurosciences, University of Montreal, CHU Sainte-Justine , Montreal

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2026 in Neuro-Oncology
Verified
Journal Article
Open access
DKDorsa Sadat Kiaei
Dorsa Sadat Kiaei
MCMaxime Caru
Maxime Caru
VLValérie Larouche
Valérie Larouche
ECEmma Clini
Emma Clini
DSDeepika Pugalenthi Saravanan
Deepika Pugalenthi Saravanan
Sébastien PerreaultSébastien Perreault
Sébastien Perreault
Background: Plexiform neurofibromas (PNs) are observed in up to 50% of patients with neurofibromatosis type 1 (NF1). Trametinib has been used widely to treat PNs but limited data has been reported on its efficacy within a clinical trial. We conducted a phase 2 trial with trametinib for patients with NF1 and inoperable PNs. Methods: Patients with NF1 and inoperable PNs aged ≥1 month to ≤25 years when starting trametinib were eligible. Patients received trametinib once daily orally continuously for a maximum of 18 cycles of 28 days. Patients completed patient-reported outcome measures. Response evaluations were performed after cycle 3, 6, 12 and at the end of treatment and then every 6 months. The PN volumes were centrally quantified using a semi-automatic 3D segmentation method. Results: Forty-six patients were recruited. The median age was 11.1 years (range 0.7-19.8). The median baseline tumor volume was 104.6 ml (range 16.3 to 650.1 ml). Volumetric assessment demonstrated an overall response rate (volume decrease of ≥20%) in 47.8% (22/46) of patients. Median volume change was −19.3% (range −80.5 to 3.5). Forty-one patients (89.1%) completed the planned treatment. The 3 years progression free survival and the event free survival were respectively 73.1% (95% CI 53.3%-85.5%) and 47.1% (95% CI 28.8-63.5). Conclusions: We report outcomes and volumetric response of PNs treated with trametinib within a phase 2 trial. Based on these results, trametinib is effective and overall well tolerated.

23 December 2025 in Neurological Research
Verified
Journal Article
Closed access
KEKarim Estephan
Karim Estephan
LCLaurence Charbonneau
Laurence Charbonneau
FCFella Chennou
Fella Chennou
RJRoland Jabre
Roland Jabre
MDMartin Y. Desrosiers
Martin Y. Desrosiers
RMRobert Moumdjian
Robert Moumdjian
To evaluate remission, recurrence, and complication rates following endoscopic transsphenoidal surgery (ETSS) for Cushing disease (CD) at a Canadian tertiary center, and assess concordance of preoperative cerebral MRI and inferior petrosal sinus sampling (IPSS) with intraoperative adenoma laterality. We retrospectively reviewed 92 patients with confirmed CD who underwent ETSS by a single neurosurgeon between August 2007 and May 2025. Outcomes included biochemical remission, recurrence, and complications. We assessed the concordance of preoperative MRI and IPSS with intraoperative tumor localization. The cohort included 92 patients (mean age 46.6 ± 15.0 years; 77% female) with a median follow-up of 18.3 months (IQR 6.4-44.9). Preoperative MRI identified a microadenoma in 63 cases, macroadenoma in 17, and was negative in 12. Remission was achieved in 76.7% (86.4% early ≤6 months), with 7.9% experiencing recurrence after a median of 13.2 months. Complications included arginine vasopressin deficiency (AVPD) in 43.5% of the cohort (persistent >6 months in 10.2%), hypothyroidism in 14.1%, syndrome of inappropriate antidiuretic hormone secretion (SIADH) in 5.4%, and cerebrospinal fluid (CSF) leak in 3.3%. Intraoperatively, 78.8% of microadenomas were in the posterior adenohypophysis, and 27.4% exhibited multifocal distribution. Concordance of adenoma laterality was 56.5% for MRI and 41.7% for IPSS, with no statistically significant difference. ETSS achieved high remission with low morbidity in CD. Frequent posterior and multifocal adenomas in the adenohypophysis support systematic pituitary exploration. Localization remains challenging, with limited concordance using MRI and IPSS, highlighting the need for cautious interpretation in surgical planning.

13 September 2026 in The Laryngoscope
Verified
Journal Article
Open access
PDF file
KEKarim Estephan
Karim Estephan
MBMathieu Bergeron
Mathieu Bergeron
Objective: To map and synthesize the evidence on epiglottopexy in pediatric patients with laryngomalacia, epiglottic prolapse, and obstructive sleep apnea (OSA) with attention to indications, techniques, outcomes, complications, and evidence gaps. Data Sources: PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar were searched from January 1980 to May 2026 for English‐ and French‐language studies, supplemented by hand‐searching of reference lists. Review Methods: This scoping review followed PRISMA‐ScR guidelines. The review protocol was registered on OSF prior to data extraction. Eligible studies were original reports of pediatric patients (< 18 years) who underwent epiglottopexy for any indication. Two reviewers independently screened records and extracted data; findings were synthesized descriptively. Results: Twenty‐four studies (371 patients) published between 1987 and 2026 met inclusion criteria, comprising case reports, case series, and retrospective cohorts from 10 countries. Surgical approaches included endoscopic CO 2 laser or cautery‐assisted glossoepiglottopexy, transoral suture‐based epiglottopexy, transcervical external fixation, and robot‐assisted epiglottopexy. Indications spanned classic Type III laryngomalacia, epiglottic prolapse complicating tracheostomy‐dependent or syndromic airway disease, and increasingly, drug‐induced sleep endoscopy (DISE)‐confirmed epiglottic obstruction in children with refractory OSA. Respiratory improvement was consistently reported, swallowing function was largely preserved or improved, and complication and recurrence rates were low, with single‐procedure success in most cases. Conclusion: Epiglottopexy is reported to be safe and effective for pediatric epiglottic prolapse across diverse clinical contexts and techniques. DISE has expanded its indications to sleep‐state‐dependent epiglottic obstruction. Evidence remains limited by small, retrospective series; prospective studies with standardized DISE protocols, outcome measures, and longer follow‐up are needed. Level of Evidence: N/A.

17 July 2026 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Verified
Journal Article
Open access
PDF file
WDWilliam Davalan
William Davalan
AGAlexandrine Gagnon
Alexandrine Gagnon
TBTristan Brunette-Clément
Tristan Brunette-Clément
CRClaudia Restrepo
Claudia Restrepo
KEKarim Estephan
Karim Estephan
PLPascal Lavergne
Pascal Lavergne
Background and objective: Direct cerebral revascularization remains a central therapeutic approach for Moyamoya disease (MMD) and Moyamoya syndrome (MMS). However, existing outcome data are largely derived from East Asian populations, with limited evidence characterizing North American cohorts. This study presents the experience of a Canadian university hospital with superficial temporal artery–middle cerebral artery (STA–MCA) bypass for MMD and MMS, focusing on perioperative management, surgical outcomes and graft durability. Methods: A retrospective case series was conducted, including nine patients with MMD/MMS who underwent STA–MCA bypass between December 2021 and March 2026 at the Hôpital du Sacré-Coeur de Montréal. Data on demographics, clinical presentation, perioperative care and follow-up outcomes were analyzed. Primary outcomes included bypass graft patency and ischemic or hemorrhagic events. Secondary outcomes included functional status assessed via the modified Rankin Scale and perioperative complications. Results: All patients ( n = 9) demonstrated sustained graft patency, with a median clinical follow-up of 16 months and a median radiological follow-up of 14 months. Eight patients (89%) experienced stable functional outcomes, while one (11%) experienced significant neurological decline due to postoperative complications. No ischemic events were observed during follow-up; however, one patient experienced a subdural hematoma in the immediate postoperative period, necessitating surgical intervention. Conclusion: Direct STA–MCA bypass is a viable revascularization strategy for MMD/MMS, achieving high graft patency and preventing recurrent ischemic events. It can be safely established in a Canadian center. However, the potential for complications, particularly in high-risk patients, highlights the critical importance of meticulous perioperative management and careful patient selection.